Jessicca Rege of Alkermes provides insights into how protein engineering approaches have led to the development of novel therapies that harness the immune system’s capabilities to fight cancer.
The field of immunotherapy is constantly evolving with the ultimate goal to develop new treatments that help the body’s immune system fight cancer. Immune cells, such as T cells and natural killer (NK) cells, have the inherent ability to combat diseases, including cancer, but are often inhibited by the body’s own suppressive mechanisms. Cancer immunotherapies such as checkpoint inhibitors (CPIs) were designed to counteract these. Today, there are many approved immunotherapy approaches that can enhance the anti-tumour activity of immune cells, resulting in improved survival rates. However, even as science advances, there remain patients who still need new treatment options. By re-engineering existing approaches that have already shown clinical promise, there is potential to bring further benefit to the patient community in its fight against cancer.
Unlocking the potential of immunotherapies
Decades ago, antibodies targeting the protein CD20, found on B cells, revolutionised the way we treat some leukaemias and lymphomas. Since then, several next-generation antibodies have been engineered with modifications that enable them to better engage with immune cells.1 For example, the antibody obinutuzumab was engineered with modified sugars on the fragment crystallisable (Fc) portion of the antibody, providing greater potential to induce anti-tumour efficacy. A new therapeutic antibody class, bispecific antibodies, was engineered to build on the classic antibody design and bind to two different proteins, demonstrating how incremental changes in protein design can lead to entirely new therapies.2
Another immunotherapy treatment option, CAR T-cell therapy, involves collecting a patient’s T cells and engineering them to produce surface proteins known as chimeric antigen receptors (CARs).3 The CARs recognise and bind to proteins on the surface of cancer cells, effectively killing them. CAR T-cell therapies have been approved to treat multiple cancer types, including blood cancers such as lymphomas, multiple myeloma and some leukaemias. However, to date its application for solid tumours has been challenging. Additionally, CAR T-cell therapies must be customised for each patient, potentially making therapy access challenging. To address this, several companies are investigating advanced biomedical engineering techniques, such as CRISPR, to generate novel CAR T-cell therapies with shorter wait times.4
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Cytokines are immune-signalling proteins that have long shown promise as a therapeutic option for many diseases including cancer. A synthetic version of the cytokine interleukin-2, or IL-2, known for its potent effects on immune cells, was approved to treat metastatic melanoma and kidney cancer more than 20 years ago – making it the first approved immuno‑oncology treatment. Although IL-2 was recognised as an efficacious treatment, clinical use was limited by toxicity issues. IL-2 therapy is associated with safety concerns, namely the adverse event capillary leak syndrome, which often leads to hospitalisations and thus limits its clinical use. In addition, high doses of native IL-2 can activate suppressive immune cells that counteract the anti‑tumour effects of CD8 T cells and NK cells.5
With the advent of new protein engineering capabilities and the increasing understanding of the immune system, researchers are now able to design cytokines intended to mitigate some of these issues. The field of IL‑2‑based immunotherapy is an example of such novel design approaches.
Several companies have focused on developing investigational IL-2 therapies, utilising advanced technologies to re‑engineer the IL-2 protein to retain its anti-tumour effects while minimising safety concerns. Protein engineering comes with several challenges, including maintaining stability and immunogenicity of the novel protein and creating an inherently active drug. Some approaches have relied on introducing chemical entities to the IL-2 protein, with the goal to direct its activity only towards cancer‑fighting immune cells. Others have modified IL-2 to be administered as a prodrug that is activated inside the body via metabolic cleavage. While these approaches have validated the potential of IL-2 as an immunotherapy, full clinical development has been hindered by suboptimal data in clinical trials, further underscoring the challenges of effectively re-engineering this molecule.
Immunotherapies help the immune system recognise and attack cancer cells.
Additionally, clinical trials of novel immunotherapies, including IL-2–based therapies, are often designed using combinations with immune checkpoint blockade, making it difficult to isolate monotherapy activity of the investigational agent. Establishment of single-agent activity is a critical component to consider in the development of new drugs, as eliciting the component effect of each molecule (in a combination) is critical in clinical development and, ultimately, regulatory approval.
At Alkermes, we have taken a unique approach to redesigning IL‑2. Our investigational IL-2 therapy nemvaleukin alfa (nemvaleukin), is an engineered fusion protein developed by fusing a modified IL-2 protein with a subunit of its own receptor, the high‑affinity IL-2 receptor alpha chain.6 This molecule was designed with the goal of retaining anti-tumour activity of IL-2 and preferentially expanding anti‑tumour immune cells (T cells and NK cells) while mitigating potential drawbacks of high-dose native IL-2 that lead to immunosuppression and toxicity. The molecule is a stable fusion protein that is administered as an active drug and does not degrade into native IL-2 inside the body. Early clinical trials have demonstrated clinical activity of nemvaleukin in patients pretreated with CPIs, as monotherapy, and in combination with pembrolizumab in tumour types, including those that are approved and unapproved for pembrolizumab treatment.
Protein engineering comes with several challenges, including maintaining stability and immunogenicity of the novel protein and creating an inherently active drug
In these early studies, particularly encouraging results were seen in mucosal melanoma and platinum-resistant ovarian cancer (PROC), which are both difficult-to-treat tumour types. Data from these early studies have paved the way for ongoing, later-phase clinical trials in mucosal melanoma and PROC. Nemvaleukin is being investigated as a monotherapy for patients with mucosal melanoma who progressed on immune CPIs, and for PROC as monotherapy and in combination with pembrolizumab. Nemvaleukin received several regulatory designations for development programmes from the US Food and Drug Administration (FDA) in 2021: Orphan Drug Designation and Fast Track Designation for mucosal melanoma and Fast Track Designation for the treatment of PROC. Additionally, nemvaleukin received entry into the Innovative Licensing and Access Pathway (ILAP) in the UK earlier this year for the treatment of mucosal melanoma.
Re-engineered immunotherapies: a turning point for immuno-oncology
Re-engineered immunotherapies have the potential to provide new treatment options in oncology that may help expand the range of cancers and the patient population that can be treated with these therapies. As continued research deepens our understanding of protein engineering and the immune system, we will continue to work relentlessly to develop new treatment options for oncology patients with difficult-to-treat tumour types.
About the author
Jessicca Rege, PhD serves as Vice President, Clinical Research Oncology at Alkermes, where she is responsible for establishing the company’s immuno-oncology development strategy and overseeing the execution of its global clinical trials. Dr Rege joined Alkermes in 2020, bringing with her more than 15 years of experience in research, clinical development and global medical affairs. She previously held roles of increasing responsibility at Bristol-Myers Squibb, Eisai, Daichi Sankyo and Boehringer Ingelheim. Dr Rege earned a Bachelor of Science from Carson-Newman, and holds both a Master of Science in Physiology and a PhD in Pharmaceutical Sciences from Virginia Commonwealth University. She completed her postdoctoral fellowship in paediatric leukemia at the University of Pennsylvania’s Children’s Hospital of Philadelphia.
References
Alduaij W, Illidge T. The future of anti-CD20 monoclonal antibodies: Are we making progress? Blood. 2011; 117(11): 2993–3001.
Salvaris R, Ong J, Gregory GP. Bispecific antibodies: A review of development, clinical efficacy and toxicity in B-cell lymphomas. J. Pers. Med. 2021; 11(5): 355.
Alnefaie A, Albogami S, Asiri Y, et al. Chimeric antigen receptor T-cells: An overview of concepts, applications, limitations, and proposed solutions. Front. Bioeng. Biotechnol. 2022; 10.
Dimitri A, Herbst F, Fraietta J. Engineering the next-generation of car T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022; 21(1).
Tang A, Harding F. The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer. Cytokine: X. 2019; 1(1): 100001.
Lopes J, Fisher J, Flick H, et al. Alks 4230: A novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020; 8(1).
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.